Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'
Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments Highlighted clinical cases that improved the safety of anti-amyloid therapy...
Crown Prince of Selangor Officiates Launch of UNESCO Southeast Asia Entrepreneurship Education Network in Kuala Lumpur
A Landmark Moment Aligning ASEAN Youth Empowerment with Regional Education Transformation KUALA LUMPUR, Malaysia, Nov. 27, 2025 /PRNewswire/ -- His Highness Tengku Amir Shah ibni Sultan Sharafuddin Idris Shah Al-Haj, Crown Prince of Selangor,...
Ping An Unveils "Ancient Tree Guardian Action" at UN Climate Change Conference (COP30)
Leveraging an Innovative "Insurance + Technology" Approach to Safeguard 55,000 Ancient Trees and Promote Biodiversity Conservation HONG KONG and SHANGHAI, Nov. 24, 2025 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or...
Chinese-Style Green Wisdom: Global Gen Z Discovers Jinan's Charm Through Culture and Innovation
BEIJING, Nov. 10, 2025 /PRNewswire/ -- A news report from China Daily: At the Quehua Ecological and Cultural Zone in Jinan Start-up Area for Growth Drivers Transformation, Shandong Province, French youth RIVOIRE Oceane Anna, along with her peers,...
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA),...
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of...
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian...
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily...
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other
AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients...
BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes and overweight, non-obese individuals Preclinical data for BGM1812 supports...